The online version of this article (doi:10.1186/s13075-017-1236-x) contains supplementary material, which is available to authorized users.
The inhibition of pyrimidine biosynthesis by blocking the dihydroorotate dehydrogenase (DHODH) activity, the prime target of leflunomide (LEF), has been proven to be an effective strategy for rheumatoid arthritis (RA) treatment. However, a considerable proportion of RA patients are refractory to LEF. Here, we investigated lapachol (LAP), a natural naphthoquinone, as a potential DHODH inhibitor and addressed its immunosuppressive properties.
Molecular flexible docking studies and bioactivity assays were performed to determine the ability of LAP to interact and inhibit DHODH. In vitro studies were conducted to assess the antiproliferative effect of LAP using isolated lymphocytes. Finally, collagen-induced arthritis (CIA) and antigen-induced arthritis (AIA) models were employed to address the anti-arthritic effects of LAP.
We found that LAP is a potent DHODH inhibitor which had a remarkable ability to inhibit both human and murine lymphocyte proliferation in vitro. Importantly, uridine supplementation abrogated the antiproliferative effect of LAP, supporting that the pyrimidine metabolic pathway is the target of LAP. In vivo, LAP treatment markedly reduced CIA and AIA progression as evidenced by the reduction in clinical score, articular tissue damage, and inflammation.
Our findings propose a binding model of interaction and support the ability of LAP to inhibit DHODH, decreasing lymphocyte proliferation and attenuating the severity of experimental autoimmune arthritis. Therefore, LAP could be considered as a potential immunosuppressive lead candidate with potential therapeutic implications for RA.
Additional file 1: Figure S1. Mean concentration–time profiles of lapachol after (A) 2 mg/kg i.v., (B) 10 mg/kg oral, and (C) 25 mg/kg oral administration to rats. Data points are mean ± standard deviation. (PDF 146 kb)13075_2017_1236_MOESM1_ESM.pdf
Additional file 2: TableS1. LAP and LAP sodium salt pharmacokinetic parameters determined by noncompartmental and compartmental approaches after i.v. administration of 2 mg/kg in Wistar rats. (PDF 93 kb)13075_2017_1236_MOESM2_ESM.pdf
Additional file 3: Table S2. Pharmacokinetic parameters after oral administration of lapachol (10 mg/kg and 25 mg/kg) and LAP sodium salt (30 mg/kg) in Wistar rats. (PDF 79 kb)13075_2017_1236_MOESM3_ESM.pdf
Additional file 4: Figure S2. Superimposition of the crystallographic hDHODH inhibitor A771726 (PDB id:1D3H, carbon atoms in cyan) and the top-ranked docking solution (carbon atoms in yellow), inside the active site. (PDF 458 kb)13075_2017_1236_MOESM4_ESM.pdf
Additional file 5: Table S3. Evaluation of the toxicity of lapachol in proliferating CD4 T cells. (PDF 224 kb)13075_2017_1236_MOESM5_ESM.pdf
Additional file 6: Figure S3. Serum levels of GPT and AST in LAP-treated mice during CIA protocol. (PDF 518 kb)13075_2017_1236_MOESM6_ESM.pdf
Additional file 7: Figure S4. Serum titers of anti-mBSA antibodies in LAP-treated mice on antigen-induced arthritis (AIA). (PDF 767 kb)13075_2017_1236_MOESM7_ESM.pdf
Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol (Hoboken, NJ). 2016;68:1–26.
Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gömör B, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2000;39:655–65. CrossRef
Hussain H, Krohn K, Ahmad VU, Miana GA, Green IR. Lapachol: an overview. Arkivoc. 2007;2007:145–71. CrossRef
Kathawate L, Joshi PV, Dash TK, Pal S, Nikalje M, Weyhermüller T, et al. Reaction between lawsone and aminophenol derivatives: synthesis, characterization, molecular structures and antiproliferative activity. J Mol Struct. 2014;1075:397–405. CrossRef
Oramas-Royo S, Torrejón C, Cuadrado I, Hernández-Molina R, Hortelano S, Estévez-Braun A, et al. Synthesis and cytotoxic activity of metallic complexes of lawsone. Bioorganic Med Chem. 2013;21:2471–7. CrossRef
Baggish AL, Hill DR. Antiparasitic agent atovaquone. Antimicrob. Agents Chemother. 2002;46:1163–73.
Epifano F, Genovese S, Fiorito S, Mathieu V, Kiss R. Lapachol and its congeners as anticancer agents: a review. Phytochem Rev. 2014;13:37–49.
Balassiano IT, De Paulo SA, Silva NH, Cabral MC, Carvalho MC. Demonstration of the lapachol as a potential drug for reducing cancer metastasis. Oncol Rep. 2005;13:329–33. PubMed
FDA Guidance for industry, bioanalytical method validation US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2001.
Asquith MJ, Boulard O, Powrie F, Maloy KJ. Pathogenic and protective roles of MyD88 in leukocytes and epithelial cells in mouse models of inflammatory bowel disease. Gastroenterology. 2010;139:519–529.
Raza K, Scheel-Toellner D, Lee C-Y, Pilling D, Curnow SJ, Falciani F, et al. Synovial fluid leukocyte apoptosis is inhibited in patients with very early rheumatoid arthritis. Arthritis Res Ther. 2006;8:1–7. CrossRef
- Lapachol, a compound targeting pyrimidine metabolism, ameliorates experimental autoimmune arthritis
Raphael S. Peres
Gabriela B. Santos
Nerry T. Cecilio
Valquíria A. P. Jabor
Bruna G. S. Torres
Carlos H. T. P. Silva
Teresa Dalla Costa
Norberto P. Lopes
Maria C. Nonato
Fernando S. Ramalho
Thiago M. Cunha
Fernando Q. Cunha
Flavio S. Emery
Jose C. Alves-Filho
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II